Comparing text messaging and patient portal systems for reporting symptoms in multiple myeloma patients
Testing Two Implementation Strategies in Collecting ePRO Among Multiple Myeloma Patients: ePRO4MM
This study is testing whether patients with multiple myeloma prefer using text messaging or a patient portal to report their symptoms and how satisfied they are with each method.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Thomas Jefferson University Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT06041698 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates patient satisfaction and engagement with two different electronic platforms for reporting symptoms among patients with multiple myeloma. Participants will be assigned to either a text messaging platform (TXT-Chatbot) or a patient portal system (MyChart) to report their health status over a period of six months. The study aims to assess patients' preferences, adherence to the chosen method, and the usability of each approach. Additionally, it will explore differences in preferences and response rates based on race and the chosen reporting method.
Who should consider this trial
Good fit: Ideal candidates for this study are adults diagnosed with multiple myeloma who can use text messaging or have internet access.
Not a fit: Patients under 18 years of age or those with documented cognitive impairments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the way patients with multiple myeloma report symptoms, potentially improving their quality of life and clinical outcomes.
How similar studies have performed: Other studies have shown success with electronic patient-reported outcomes, indicating that this approach is promising and not entirely novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of MM * Able to use TXT or have Internet access * Can read and understand English * If patients are undergoing an autologous stem cell transplant, they will be enrolled after their transplant Exclusion Criteria: * \< 18 years of age * Cognitive impairment documented in the electronic medical record (EMR)
Where this trial is running
Philadelphia, Pennsylvania
- Sidney Kimmel Cancer Center at Thomas Jefferson University — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Study coordinator: Kuang-Yi Wen, PhD
- Email: Kuang-Yi.Wen@Jefferson.edu
- Phone: 215-503-4623
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.